2-ethyl-2-hydroxy-N'-(p-tolyl)butanehydrazide
ADVERTISEMENT
- Molecular formula
- C13H20N2O2
- CAS Number
- 68333-86-2
- IUPAC Name
- 2-ethyl-2-hydroxy-N'-(p-tolyl)butanehydrazide
- Molecular Weight
- 222.30g/mol
- Melting Point
- (Celsius)
- Boiling Point
- (Celsius)
- Density
- 1.1560g/cm3
- Synonyms
- Diethylglycolic acid p-tolylhydrazide
Identification
Interesting facts
Interesting Facts about 2-Ethyl-2-Hydroxy-N'-(p-Tolyl)butanehydrazide
2-Ethyl-2-hydroxy-N'-(p-tolyl)butanehydrazide is a fascinating chemical compound with various applications in organic chemistry and medicinal research. Here are some key points to consider:
- Reactivity: This compound features a hydrazide functional group, which makes it particularly reactive with various electrophiles and nucleophiles. This enhances its utility in synthetic organic chemistry.
- Biological Activity: Hydrazides, including this one, have been studied for their potential biological activity. Some hydrazide derivatives exhibit antibacterial and antitumor properties, making them valuable in pharmaceuticals.
- Synthesis: The synthesis of this compound often involves the reaction of hydrazine derivatives with carbonyl compounds. Understanding these synthetic pathways is essential for chemists looking to create derivatives with modified properties.
- Functionalization: The presence of both ethyl and p-tolyl groups in its structure allows for further functionalization. This means that chemists can modify the compound to enhance its properties or create novel materials.
- Research Potential: Due to its complex structure, 2-ethyl-2-hydroxy-N'-(p-tolyl)butanehydrazide serves as a subject of interest for researchers investigating structure-activity relationships in drug design.
In summary, 2-ethyl-2-hydroxy-N'-(p-tolyl)butanehydrazide stands as a noteworthy compound not just for its chemical structure, but also for its potential applications in various fields of chemistry and biology. As scientists continue to explore its properties, it may pave the way for the development of new therapeutic agents.